Neeraj Agarwal, Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute, shared a post on X about a paper by Tom Powles et al. published in Annals of Oncology:
“Just in Annals of Oncology by Tom Powles, Petros Grivas and team.
Ph3 TROPiCS-04 trial result.
Sacituzumab govitecan (SG) vs physician’s choice chemoRx in pretreated mUC bladder cancer.
No OS or PFS benefit with SG.”
“Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial”
Authors: Tom Powles, Petros Grivas et al.
More posts featuring Neeraj Agarwal.
